Replies to post #138123 on Biotech Values

[jq1234]

FDA has agreed to an EDSS score primary endpoint for a new phase III study for Laquinimod

Thanks for the info. I assume this is another 24-month trial as BRAVO. It will take 3-4 years to complete the new trial. Even if it meets EDSS endpoint, not sure if Laquinimod is relevant at that time.